Mode
Text Size
Log in / Sign up
N/A N=826

MedStar Diabetes Pathway Chart Reviews

Type2 Diabetes Mellitus

Enrolled (actual)
826
Serious AEs
1.1%
Results posted
Oct 2020
Primary outcome: Primary: Percent Change in A1C — -3.06; -1.44 % change — p=<0.001

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Intensive diabetes education and medication management (Other)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Medstar Health Research Institute
Primary completion
Dec 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent Change in A1C
-3.06; -1.44 <0.001 sig
SECONDARY
Risk for Emergency Room Visits at 30 Days From Baseline as Measured by Incidence Risk Ratio
0.79; 0.39
SECONDARY
Risk for Hospitalizations at 30 Days From Baseline
0.21; 1.14
SECONDARY
Risk for Composite of Emergency Room Visits and Hospitalizations at 30 Days From Baseline
0.55; 0.53
SECONDARY
Risk for Emergency Room Visits at 90 Days From Baseline
0.62; 0.66
SECONDARY
Risk for Hospitalizations at 90 Days From Baseline
0.23; 1.58
SECONDARY
Composite of Risk for Hospitalizations and Emergency Room Visits Within 90 Days From Baseline
0.49; 0.80

Summary

The MedStar Diabetes Pathway (MDP) is transitioning into a clinical program offered at various MedStar sites. The MDP clinical team is reviewing the data collected during the pilot to improve the program and adapt it to various clinical settings in order to better serve the target patient population. It is imperative to continue reviewing patient clinical outcomes as the program expands in order to insure continuous quality improvement of the program. This will be achieved through chart reviews of patients receiving diabetes care via the MDP and comparison with patients received diabetes standard of care through their primary care physician.

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of Type 2 Diabetes, A1C equal or higher than 9%, active patient of medstar health provider, english speaking, willing and able to participate in the program

Exclusion Criteria

  • A1C less than 9%, severe illness that precludes participation such severe congestive heart failure or COPD, advanced kidney disease, recent acute illness such as heart attack or stroke in the past 30 days, active cancer, severe mental illness, high dose steroid, other types of diabetes, pregnant or lactating.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03442595). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search